

RESEARCH

Open Access

Orthostatic plasma norepinephrine level as a predictor for therapeutic response to metoprolol in children with postural tachycardia syndrome

Qingyou Zhang¹, Xia Chen², Jiawei Li¹ and Junbao Du^{1,3*}

Abstract

Background: Postural tachycardia syndrome (POTS) is a heterogeneous disorder that creates challenges for treatment. Beta-blocker was one of the most commonly used drugs, but it is inconsistently effective. The purpose of this study is to explore whether orthostatic plasma norepinephrine level could be an indicator of therapeutic effectiveness of metoprolol for POTS in children.

Methods: Twenty-seven children with POTS were enrolled in our study. They received metoprolol treatment, and their orthostatic plasma norepinephrine levels were measured by high-performance liquid chromatography method. Three months after metoprolol treatment, 25 patients were followed up. A receiver-operating characteristic (ROC) curve was used to explore the predictive value of orthostatic plasma norepinephrine level.

Results: The symptom severity and increment of heart rate from supine position to upright of patients positively correlated with their orthostatic plasma norepinephrine level ($r = 0.599$, $P < 0.001$; $r = 0.633$, $P < 0.001$, respectively). Orthostatic plasma norepinephrine level in responders to metoprolol was significantly higher than that of nonresponders ($P = 0.028$). A ROC curve on the predictive value of orthostatic plasma norepinephrine level showed that the area under the curve was 0.785. Using a cutoff value for orthostatic plasma norepinephrine level of 3.59 pg/ml yielded both sensitivity (76.9%) and specificity (91.7%) in predicting the efficacy of metoprolol therapy for POTS.

Conclusion: Orthostatic plasma norepinephrine level of > 3.59 pg/ml was an indicator of the effectiveness of metoprolol therapy for POTS in children and adolescents.

Keywords: Norepinephrine, Postural tachycardia syndrome, Metoprolol

Background

Postural tachycardia syndrome (POTS) is a heterogeneous disorder characterized by sustained tachycardia (≥ 30 bpm in adults and ≥ 40 bpm in children) upon standing, and relief of these symptoms with recumbence. Although the underlying causes of POTS remain unclear, several mechanisms have been proposed, including sympathetic activation, hypovolemia, and partial autonomic neuropathy [1-4]. POTS is associated with a poor quality of life and significantly functional disability [5].

There is a paucity of effective therapies [1,4]. Because of the striking tachycardia that is central to this disorder, these patients are often referred to cardiologists for diagnosis and treatment. Given that excessive tachycardia is a cardinal feature of this syndrome, a logical treatment strategy would be reducing the HR with β -adrenergic blockade. β -blockers have been reported to improve symptoms in case reports and open-label studies [6-10]. Unfortunately, it is inconsistently effective [11,12]. Differences in noradrenergic activity between hyperadrenergic and other types of POTS may explain this inconsistency, and previous studies of efficacy of β -blockers in POTS subjects did not stratify participants into POTS subtypes according to their underlying causes. Hyperadrenergic subgroup with β -blockers would seem reasonable.

* Correspondence: junbaodu1@126.com

¹Department of Pediatrics, Peking University First Hospital, Xi-An Men Street No. 1, West District, Beijing 100034, PR China

³Key Laboratory of Molecular Cardiology, Ministry of Education, Beijing 100019, PR China

Full list of author information is available at the end of the article

Furthermore, β -blockers can impair exercise tolerance in healthy subjects [13]. Higher-dose of β -blocker might worsen symptoms of patients with POTS, which raises the concern that the effectiveness of β -blockers in POTS might depend on noradrenergic activity of patients with POTS. Our hypothesis is that the orthostatic plasma norepinephrine level could help guiding β -blocker therapy in the management of POTS in children.

Methods

Subjects

Twenty-seven children (mean age, 11 years, ranging from 6 years to 15 years) were diagnosed as POTS at the Department of Pediatrics, Peking University First Hospital. Our study referred to the following criteria [14-17]: 1) a child has a normal heart rate at supine and no evidence of any cardiovascular diseases; 2) after standing up or getting up, a child has 2 of the following symptoms: dizziness, chest distress, chest pain, headache, palpitation, pale face, amaurosis, fatigue, discomfort, or syncope; 3) these symptoms should be relieved or diminished by recumbence, and the symptoms should occur repeatedly for 1 month; 4) in addition to the symptoms of orthostatic intolerance, POTS is diagnosed with the quantitative sign of a heart rate increase of 40 beats/min or greater or a heart rate of > 120 beats/min within the first 10 min after standing during head-up test (HUT) or head-up tilt test (HUTT); simultaneously, the decrease of blood pressure should be $< 20/10$ mm Hg; and 5) children with other diseases that cause symptoms of autonomic nervous system (such as anemia, arrhythmia, hypertension, or endocrine disorders including pheochromocytoma or hyperthyroidism) as well as cardiogenic or neurogenic diseases that would induce syncope were excluded. The study has been conducted according to the principles expressed in the Declaration of Helsinki. The written informed consent had been obtained from each individual and their parents and the study protocol was approved by the Ethics Committee of Peking University First Hospital (the approval number: 2012 [525]).

HUTT protocol

All patients received tilt table testing. All examinations occurred between 8:00 AM and 10:00 AM in a quiet and bland light room at a comfortable constant ambient temperature (22°C, 50% to 55% humidity). Patients were secured to a tilt table, and HR and BP were monitored for 10 min. Patients were then tilted upward at angle of 60° for 45 min. Then, blood pressure and heart rate were monitored and electrocardiogram was recorded simultaneously during the test (Dash 2000 Monitor, GE Company, U.S.A). The patients were placed in the supine from the standing position as soon as the positive response or symptoms of orthostatic intolerance (OI) occurred. The symptoms of OI included lightheadedness,

diminished concentration, tremulousness, nausea, headache, near syncope or syncope. A sustained heart rate increase ≥ 40 beats/min or a sustained rate of 120 beats/min in the first 10 min of passive upright tilt is considered diagnostic [17,18].

Assay orthostatic plasma norepinephrine

After patients rested for 30 min or longer, they remained standing position for 5 min, and then blood samples were collected. Blood samples were centrifuged at 3,000 rpm for 10 min immediately after collection, and plasma was frozen for -20°C until analysis. Plasma catecholamine levels were determined by high-performance liquid chromatography with electrochemical detection [19].

Protocol of treatment and follow-up

All 27 patients were prescribed metoprolol for therapy. The dose of metoprolol was 0.5 mg/kg daily, twice a day. Follow-up in our cardiology clinic was conducted after 3 month of therapy, and the children and their parents were asked to report any changes in symptoms of orthostatic intolerance.

POTS symptoms were evaluated in children with the severity of symptoms for symptom scores [17,20,21]. Symptom score criteria: the following symptoms: dizziness, headache, shortness of breath, gastrointestinal symptoms, fatigue, pallor, blurred vision, palpitations, sweating, tremulousness, according to their frequency of OI symptoms graded from 0 to 4. Score 0 stands for no symptoms occurrence during follow up; score 1: 1 episode of OI symptom occurrence per month; score 2: 2 to 4 episodes of symptoms occurrence per month; score 3: 2 to 7 episodes of symptoms occurrence per week; 4: more often once daily. The therapy was determined to be effective, when the symptom of OI disappeared or symptoms scores decreased less than 50 percent [22].

Statistical analysis

Statistical analysis was done using SPSS13.0 (SPSS Inc, Chicago, IL, USA). Continuous variables were compared using Student's *t*-test and analysis of variance; categorical variables were compared using Fisher's exact test, and qualitative variables were compared using Pearson's chi-square test. A P value < 0.05 was considered to be statistically significant. The relationship between symptom severity and increment of heart rate from supine position to standing with orthostatic plasma norepinephrine level in children with POTS was analyzed using the Pearson correlation test. A receiver-operating characteristic (ROC) curve was utilized to evaluate the predictive value of orthostatic plasma norepinephrine level in assessing the therapeutic effect of metoprolol. The area under the curve represents the predictive value, with an area of 0.5-0.7 indicating low predictive value, 0.7-0.9 indicating a moderate predictive value,

and >0.9 indicating high predictive value. If the 95% CI of the area under the curve did not contain 0.5, or if the P value was <0.05, it was suggested that orthostatic plasma norepinephrine level was a reliable predictor of the therapeutic effect of metoprolol in treating children with POTS.

Results

Mean age for all 27 POTS patients was 11 ± 6 years, ranging from 6 to 15 years. There was female predominance (females: males: 15:12). The mean BMI of 27 patients was 18.6 ± 3.7 . Supine HR and BP were shown in Table 1.

Patients with severe symptoms had a high level of orthostatic plasma norepinephrine. Pearson correlation analysis revealed a significant positive correlation between symptom severity and orthostatic plasma norepinephrine ($r = 0.599$; $P < 0.001$) (Figure 1). Increment of heart rate from supine position to standing of patients with POTS also had a significantly positive correlation with orthostatic plasma norepinephrine through Pearson correlation analysis ($r = 0.633$; $P < 0.001$) (Figure 2).

During follow-up period, 2 patients did not reply despite multiple attempts at making contact. Thus, we analyzed clinical symptoms and hemodynamic changes before and after metoprolol treatment in 25 patients. Both their symptom scores and their tachycardia during HUT or HUTT were decreased obviously, when compared with those before treatment (Table 2).

In the 25 patients with POTS, who received metoprolol for therapy, 13 patients were responders, with their symptom disappearance or symptoms scores decrease less than 50 percent. The pre-treatment data, such as age, sex, symptom scores, supine blood pressure and changes in heart rates during HUT, did not differ between the 13 metoprolol responders and 12 nonresponders (Table 1).

The results showed that metoprolol responders had higher plasma levels of norepinephrine than the nonresponders, and the difference was obvious ($P < 0.05$; Table 1). The ROC curve (Figure 3) of plasma norepinephrine, for predicting the therapeutic effect of metoprolol, showed




Figure 1 Scatter plot and trend line of symptoms score and orthostatic plasma norepinephrine level of patients with POTS.

that the area under the ROC curve was 0.785 (95% confidence interval: 0.591 to 0.980, $P < 0.05$). Using a cutoff value for plasma levels of norepinephrine of 3.59 pg/ml (to convert to pg/mL, multiply by the molecular weight of norepinephrine) yielded a sensitivity of 76.9% and specificity of 91.7% in predicting the effect of metoprolol for treating POTS (Figure 3).

Discussion



Our findings showed a clear association between the orthostatic plasma norepinephrine level and symptom severity in patients with POTS. The orthostatic plasma norepinephrine level of POTS patients also associated with the increment of heart rate from supine position to standing. Especially, we found that the effectiveness of metoprolol in POTS children was related to the level of orthostatic plasma norepinephrine. Our results indicate that plasma level of norepinephrine > 3.59 pg/ml is an indicator of the effectiveness of metoprolol in children and adolescents with POTS.

Children with POTS often have symptoms of OI, such as syncope, dizziness, chest distress, chest pain, headache,

Table 1 Comparison of baseline characteristics in responders and nonresponders

Characteristics	Responders	Nonresponders	P value
Cases (n = 25)*	13	12	
Age, years	12 ± 2	11 ± 3	0.655
BMI, kg/m ² *	19.7 ± 4.9	17.2 ± 2.5	0.130
Females/males, n	7/6	6/6	0.716
Symptoms score before treatment	7.4 ± 1.9	7.2 ± 2.7	0.820
Supine systolic BP, mmHg	101.9 ± 9.3	98.0 ± 8.6	0.286
Supine diastolic BP, mmHg	58.0 ± 9.7	55.1 ± 8.1	0.426
Supine hear rate, beats/min	74.0 ± 9.4	75.6 ± 9.8	0.683
Orthostatic plasma norepinephrine level, pmol/ml	5.10 ± 2.69	2.93 ± 1.79	0.028

*Two out of 27 cases lost during follow-up.



palpitation, fatigue, and so on [1-4]. Additionally, the recurrent symptoms usually create physical and psychological stresses in children’s daily lives, both at home and school [5,23,24]. Therefore, an effective treatment, to improve symptoms, is necessary for the children with POTS.

No definite cause of primary POTS has been identified [1-4]. Exaggerated postural tachycardia may reflect several pathophysiologically distinct mechanisms. Although the precise mechanism for POTS has not been determined, given that excessive tachycardia is a cardinal feature of this syndrome, a logical treatment strategy would be to reduce the HR with β -adrenergic blockade. Raj et al. reported that low-dose oral propranolol significantly attenuated tachycardia and improved symptoms in POTS, and higher-dose propranolol did not further improve, and might worsen symptoms [8]. Arnold et al. also found recently that propranolol could improve HR control and exercise capacity in POTS when given at the low doses of propranolol for treatment [10]. We also found that metoprolol plus oral saline was effective in the treatment of POTS in children [9]. But in experimental models of orthostatic intolerance, neither propranolol, nor esmolol was found to improve

orthostatic tolerance [25-27], and Fu et al’ study suggested that for patients with POTS, propranolol was not superior to exercise training at restoring upright hemodynamics, normalizing renal-adrenal responsiveness, and improving quality of life [11]. The reasons for the different efficacy of β -blockers for treatment of POTS were differences of noradrenergic activity among distinct pathophysiological subtypes of POTS. Thieben et al. described 3 groups of patients: “hypovolemic”, “hyperadrenergic”, and “auto-immune” groups [28]. Clearly, not all cases of POTS are caused by hyperadrenergic state. Hyperadrenergic subgroup with β -blockers would seem reasonable. Thus, identifying an indicator to predict the effectiveness of β -blockers in these patients is important.

Increases in orthostatic plasma norepinephrin are the core of the biochemical changes of hyperadrenergic POTS patients. Thus, we hypothesized that orthostatic plasma norepinephrine level could predict the effectiveness

Table 2 Comparisons of symptom scores, changes of heart rate in POTS children treated by metoprolol

Treatment	Responders (n = 13)		Nonresponders (n = 12)	
	Symptoms scores	Delta HR (beats/min)	Symptoms scores	Delta HR (beats/min)
Pre-treatment	7.4 ± 1.9	55.2 ± 12.7	7.2 ± 2.7	43.6 ± 8.7
Post-treatment	0.4 ± 1.1	27.4 ± 7.8	5.0 ± 2.2	32.3 ± 9.7
P value	<0.001	<0.001	<0.001	0.001

of β -blockers in children and adolescents with POTS. In the present study, we found that higher orthostatic plasma norepinephrine level was associated with severer symptoms in children and adolescents with POTS, and there was also a positive correlation between heart rate increment on HUTT and orthostatic norepinephrine levels. These findings suggested that the excessive increase in orthostatic norepinephrine levels may result from impaired baroreflex-mediated vasoconstriction on standing in patients with POTS. These results are in keeping with previous studies of a prospective cohort of adult patients with POTS [29].

To examine the possible predictive value of plasma orthostatic norepinephrine levels, we used ROC analysis and showed that plasma levels of orthostatic norepinephrine had sensitivity of 76.9% and specificity of 91.7% in predicting the efficacy of metoprolol for treating POTS. Therefore, the plasma level of orthostatic norepinephrine could be taken as one of the reference indices in choosing medication for children with POTS.

The present study has limitations. The small sample size might have led to bias. Furthermore, we did not detect the orthostatic plasma norepinephrine level of healthy children as control group and the orthostatic plasma norepinephrine levels after the treatment of metoprolol, which was the limitation of the study. Further studies are needed to increase the case number in the multi-center design and analyze the plasma norepinephrine levels in a more comprehensive aspect. It is known that hyperadrenergic state has been well recognized one of the important mechanisms for POTS, and present study firstly provided the information about the role of plasma norepinephrine as a biomarker to predict the effect of treatment of metoprolol on POTS children.

Conclusion

Our findings suggest that the orthostatic plasma norepinephrine level could be of great help in selecting metoprolol therapy in the management of POTS in children and adolescents. The findings are of great importance for the individual therapeutic strategy of POTS in children and adolescents.

Abbreviations

POTS: Postural tachycardia syndrome; ROC: Receiver-operating characteristic; HUT: Head-up test; HUTT: Head-up tilt test; OI: Orthostatic intolerance; CI: Confidence interval.

Competing interest

The authors declare that they have no competing interest.

Authors' contribution

Dr. QZ, M.D had primary responsibility for protocol development, patient screening, enrollment, outcome assessment, preliminary data analysis and writing the manuscript. XC, M.D and JL, Ph.D drafted the manuscript and revised it critically for important intellectual content. Prof. JD, M.D supervised the design and execution of the study, performed the final data analyses and contributed to the writing of the manuscript and had a final approval of

the manuscript submitted. All authors read and approved the final manuscript.

Acknowledgments

This research was supported by Beijing Municipal Science & Technology Commission (D121107001012051), and National Twelfth 5-year Plan for Science and Technology Support (2012BAI03B03).

Author details

¹Department of Pediatrics, Peking University First Hospital, Xi-An Men Street No. 1, West District, Beijing 100034, PR China. ²Department of Pediatrics, Langfang Municipal People's Hospital, Langfang, Hebei 065000, PR China. ³Key Laboratory of Molecular Cardiology, Ministry of Education, Beijing 100019, PR China.

Received: 31 July 2014 Accepted: 29 August 2014

Published online: 10 September 2014

References

1. Medow MS: Postural tachycardia syndrome from a pediatrics perspective. *J Pediatr* 2011, **158**:4–6.
2. Jarjour IT: Postural tachycardia syndrome in children and adolescents. *Semin Pediatr Neurol* 2013, **20**:18–26.
3. Johnson JN, Mack KJ, Kuntz NL, Brands CK, Porter CJ, Fischer PR: Postural orthostatic tachycardia syndrome: a clinical review. *Pediatr Neurol* 2010, **42**:77–85.
4. Benarroch EE: Postural tachycardia syndrome: a heterogeneous and multifactorial disorder. *Mayo Clin Proc* 2012, **87**:1214–1225.
5. Benrud-Larson LM, Dewar MS, Sandroni P, Rummans TA, Haythornthwaite JA, Low PA: Quality of life in patients with postural tachycardia syndrome. *Mayo Clin Proc* 2002, **77**:531–537.
6. Wyller VB, Thaulow E, Amlie JP: Treatment of chronic fatigue and orthostatic intolerance with propranolol. *J Pediatr* 2007, **150**:654–655.
7. Freitas J, Santos R, Azevedo E, Costa O, Carvalho M, de Freitas AF: Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. *Clin Auton Res* 2000, **10**:293–299.
8. Raj SR, Black BK, Biaggioni I, Paranjape SY, Ramirez M, Dupont WD, Robertson D: Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. *Circulation* 2009, **120**:725–734.
9. Zhang Q, Du J, Wang Y: The efficacy of β -blocker plus oral saline in the treatment of children with postural orthostatic tachycardia syndrome. *J Clin Pediatr (Chinese)* 2006, **24**:357–362.
10. Arnold AC, Okamoto LE, Diedrich A, Paranjape SY, Raj SR, Biaggioni I, Gamboa A: Low-dose propranolol and exercise capacity in postural tachycardia syndrome: a randomized study. *Neurology* 2013, **80**:1927–1933.
11. Fu Q, Vangundy TB, Shibata S, Auchus RJ, Williams GH, Levine BD: Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. *Hypertension* 2011, **58**:167–175.
12. Lai CC, Fischer PR, Brands CK, Fisher JL, Porter CB, Driscoll SW, Graner KK: Outcomes in adolescents with postural orthostatic tachycardia syndrome treated with midodrine and β -blockers. *Pacing Clin Electrophysiol* 2009, **32**:234–238.
13. Ladage D, Schwinger RH, Brixius K: Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity. *Cardiovasc Ther* 2013, **31**:76–83.
14. Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, Cheshire WP, Chelimsky T, Cortelli P, Gibbons CH, Goldstein DS, Hainsworth R, Hilz MJ, Jacob G, Kaufmann H, Jordan J, Lipsitz LA, Levine BD, Low PA, Mathias C, Raj SR, Robertson D, Sandroni P, Schatz I, Schondorff R, Stewart JM, van Dijk JG: Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. *Clin Auton Res* 2011, **21**:69–72.
15. Zhang Q, Liao Y, Tang C, Du J, Jin H: Twenty-four-hour urinary sodium excretion and postural orthostatic tachycardia syndrome. *J Pediatr* 2012, **161**:281–284.
16. Singer W, Sletten DM, Opfer-Gehrking TL, Brands CK, Fischer PR, Low PA: Postural tachycardia in children and adolescents: what is abnormal? *J Pediatr* 2012, **160**:222–226.
17. Zhang F, Li X, Ochs T, Chen L, Liao Y, Tang C, Jin H, Du J: Midregional pro-adrenomedullin as a predictor for therapeutic response to midodrine

- hydrochloride in children with postural orthostatic tachycardia syndrome. *J Am Coll Cardiol* 2012, **60**:315–320.
18. Qingyou Z, Junbao D, Chaoshu T: **The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope.** *J Pediatr* 2006, **149**:777–780.
 19. Goldstein DS, Eisenhofer G, Stull R, Folio CJ, Keiser HR, Kopin IJ: **Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans.** *J Clin Invest* 1988, **81**:213–220.
 20. Winker R, Barth A, Dorner W, Mayr O, Pilger A, Ivancsits S, Ponocny I, Heider A, Wolf C, Rüdiger HW: **Diagnostic management of orthostatic intolerance in the workplace.** *Int Arch Occup Environ Health* 2003, **76**:143–150.
 21. Winker R, Barth A, Bidmon D, Ponocny I, Weber M, Mayr O, Robertson D, Diedrich A, Maier R, Pilger A, Haber P, Rüdiger HW: **Endurance exercise training in orthostatic intolerance: a randomized, controlled trial.** *Hypertension* 2005, **45**:391–398.
 22. Chen L, Wang L, Sun J, Qin J, Tang C, Jin H, Du J: **Midodrine hydrochloride is effective in the treatment of children with postural orthostatic tachycardia syndrome.** *Circ J* 2011, **75**:927–931.
 23. Benrud-Larson LM, Sandroni P, Haythornthwaite JA, Rummans TA, Low PA: **Correlates of functional disability in patients with postural tachycardia syndrome: preliminary cross-sectional findings.** *Health Psychol* 2003, **22**:643–648.
 24. Bagai K, Song Y, Ling JF, Malow B, Black BK, Biaggioni I, Robertson D, Raj SR: **Sleep disturbances and diminished quality of life in postural tachycardia syndrome.** *J Clin Sleep Med* 2011, **7**:204–210.
 25. Convertino VA, Sather TM: **Effects of cholinergic and beta-adrenergic blockade on orthostatic tolerance in healthy subjects.** *Clin Auton Res* 2000, **10**:327–336.
 26. Stewart JM, Munoz J, Weldon A: **Clinical and physiological effects of an acute alpha-1 adrenergic agonist and a beta-1 adrenergic antagonist in chronic orthostatic intolerance.** *Circulation* 2002, **106**:2946–2954.
 27. Masuki S, Eisenach JH, Schrage WG, Johnson CP, Dietz NM, Wilkins BW, Sandroni P, Low PA, Joyner MJ: **Reduced stroke volume during exercise in postural tachycardia syndrome.** *J Appl Physiol* 2007, **103**:1128–1135.
 28. Thieben MJ, Sandroni P, Sletten DM, Benrud-Larson LM, Fealey RD, Vernino S, Lennon VA, Shen WK, Low PA: **Postural orthostatic tachycardia syndrome: the mayo clinic experience.** *Mayo Clin Proc* 2007, **82**:308–313.
 29. Kimpinski K, Figueroa JJ, Singer W, Sletten DM, Iodice V, Sandroni P, Fischer PR, Opfer-Gehrking TL, Gehrking JA, Low PA: **A prospective, 1-year follow-up study of postural tachycardia syndrome.** *Mayo Clin Proc* 2012, **87**:746–752.

doi:10.1186/s12967-014-0249-3

Cite this article as: Zhang et al.: Orthostatic plasma norepinephrine level as a predictor for therapeutic response to metoprolol in children with postural tachycardia syndrome. *Journal of Translational Medicine* 2014 **12**:249.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

